Next Article in Journal
The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture
Previous Article in Journal
Human T Cell Memory: A Dynamic View
Previous Article in Special Issue
A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant
Article Menu

Export Article

Open AccessReview
Vaccines 2017, 5(1), 6; doi:10.3390/vaccines5010006

Harnessing Nanoparticles for Immunomodulation and Vaccines

1
The Jenner Institute, Oxford University, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
2
Inselspital, Universitatsspital, Sahlihaus 1, 3010 Bern, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Olga Borges
Received: 30 September 2016 / Revised: 23 January 2017 / Accepted: 25 January 2017 / Published: 14 February 2017
(This article belongs to the Special Issue Nanoparticles to Co-Deliver Immunopotentiators and Antigens)
View Full-Text   |   Download PDF [1231 KB, uploaded 14 February 2017]   |  

Abstract

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems. View Full-Text
Keywords: nanoparticles; virus-like particles; immunogen; vaccines nanoparticles; virus-like particles; immunogen; vaccines
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gomes, A.C.; Mohsen, M.; Bachmann, M.F. Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines 2017, 5, 6.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top